Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

D

Dalian University

Status and phase

Unknown
Phase 1

Conditions

Hepatocellular Carcinoma

Treatments

Drug: Placebo - Concentrate
Procedure: transcatheter arterial chemoembolization
Drug: CpG DNA

Study type

Interventional

Funder types

Other

Identifiers

NCT03235167
zsyy_zxsys2017-07

Details and patient eligibility

About

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Enrollment

100 estimated patients

Sex

All

Ages

55 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors

Exclusion criteria

having received previous treatment for liver cancer

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Quadruple Blind

100 participants in 2 patient groups, including a placebo group

CpG DNA
Experimental group
Description:
CpG DNA concentrate
Treatment:
Drug: CpG DNA
Procedure: transcatheter arterial chemoembolization
placebo
Placebo Comparator group
Description:
placebo concentrate
Treatment:
Procedure: transcatheter arterial chemoembolization
Drug: Placebo - Concentrate

Trial contacts and locations

0

Loading...

Central trial contact

haoren wang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems